The San Diego company, which has no products on the market, earned $9.5 million, or 14 cents per share, in the three months that ended Dec. 31. That compares to net income of $1.3 million, or 2 cents per share, in the final quarter of 2011.
Revenue nearly doubled to $21.9 million.
Analysts expected, on average, a loss of 8 cents per share on $9.1 million in revenue.
Aside from endometriosis, Neurocrine also is developing potential treatments for uterine fibroids, stress-related disorders, pain, diabetes and insomnia.
Elagolix is the most advanced product in its pipeline of drugs under development. Abbott Laboratories spinoff AbbVie Inc. is conducting a late-stage study of the drug as a possible endometriosis treatment, and it also is being studied in a mid-stage trial as a uterine fibroids treatment.
Neurocrine said research and development costs climbed 14 percent in the quarter to $9.1 million, and general and administrative expenses rose as well.
For the full year, Neurocrine earned $5 million, or 8 cents per share, on revenue of $53.1 million.
Looking ahead, the company expects a loss of between 75 cents and 83 cents per share in 2013. Analysts forecast, on average, a loss of 63 cents per share.
Company shares climbed more than 6 percent, or 66 cents, to $10.89 Friday in midday trading, while the Nasdaq exchange rose less than 1 percent.